Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Perrigo
16 Articles Available
Can't find what you're looking for? Try our
advanced search
.
FDA Approval
Perrigo and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Version of ProAir® HFA
PR-M02-20-NI-041
Finance
Perrigo Increases Its Dividend By 11%
PR-M04-19-NI-090
ANDA
Perrigo Confirms Patent Challenge for Generic Version of Nascobal®
PR-M03-19-NI-020
Milestone Payment
Perrigo To Receive Milestone Payment Of $250 Million From RPI Finance Trust
PR-M01-19-NI-095
Appointment
Perrigo Appoints James Dillard To Role Of Chief Scientific Officer
PR-M01-19-NI-044
FDA Approval
Perrigo Announces Tentative FDA Approval for the First To file Generic Version Of Ultravate® Lotion 0.05%
PR-M11-18-NI-107
Launch
Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%
PR-M11-18-NI-100
Patent
Perrigo Confirms Patent Challenge For Generic Version Of Kerydin®
PR-M11-18-NI-008
Financial Results
Perrigo To Release Third Quarter Calendar Year 2018 Financial Results On November 8, 2018
PR-M10-18-NI-097
Growth Strategy
Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
PR-M08-18-NI-117
Business
Perrigo to Divest Its Prescription Drug Business
PAO-M08-18-NI-015
Launch
Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn
PR-M04-18-NI-50
FDA
Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Mucinex® DM Maximum Strength Extended Release Tablets
PR-M03-18-NI-037
Appointment
Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer
PR-M02-18-NI-89
Generics
Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%
PR-M02-18-NI-90
Acquisition
Perrigo Sells API Business to SK Capital
PAO-M08-17-NI-033
.svg)
